These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 8779461)

  • 1. Resolution of heart failure in patients with AL amyloidosis.
    Dubrey S; Mendes L; Skinner M; Falk RH
    Ann Intern Med; 1996 Sep; 125(6):481-4. PubMed ID: 8779461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement.
    Dubrey SW; Cha K; Anderson J; Chamarthi B; Reisinger J; Skinner M; Falk RH
    QJM; 1998 Feb; 91(2):141-57. PubMed ID: 9578896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful heart transplantation following melphalan plus dexamethasone therapy in systemic AL amyloidosis.
    Mignot A; Bridoux F; Thierry A; Varnous S; Pujo M; Delcourt A; Gombert JM; Goujon JM; Favreau F; Touchard G; Herpin D; Jaccard A
    Haematologica; 2008 Mar; 93(3):e32-5. PubMed ID: 18310532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary amyloidosis with unusual bone involvement: reversibility with melphalan, prednisone, and colchicine.
    Schattner A; Varon D; Green L; Hurwitz N; Bentwich Z
    Am J Med; 1989 Mar; 86(3):347-8. PubMed ID: 2919619
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of Chemotherapy for Light-Chain Amyloidosis in Patients Presenting With Symptomatic Heart Failure.
    Sperry BW; Ikram A; Hachamovitch R; Valent J; Vranian MN; Phelan D; Hanna M
    J Am Coll Cardiol; 2016 Jun; 67(25):2941-8. PubMed ID: 27339491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of AL amyloidosis with melphalan, prednisone, and colchicine.
    Benson MD
    Arthritis Rheum; 1986 May; 29(5):683-7. PubMed ID: 3718560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective and well tolerated treatment with melphalan and dexamethasone for primary systemic AL amyloidosis with cardiac involvement.
    YOSHIZAWA S; AKAHANE D; FUJIMOTO H; GOTOH M; KIGUCHI T; TAUCHI T; OHYASHIKI K
    Rinsho Ketsueki; 2009 Nov; 50(11):1647-51. PubMed ID: 20009442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic light-chain amyloidosis presenting with rapid progressive heart failure.
    Sunbul M; Durmus E; Kivrak T; Besiroglu F; Gerin F; Sari I; Mutlu B
    Ther Adv Cardiovasc Dis; 2013 Aug; 7(4):224-7. PubMed ID: 23868674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis.
    Ng B; Connors LH; Davidoff R; Skinner M; Falk RH
    Arch Intern Med; 2005 Jun; 165(12):1425-9. PubMed ID: 15983293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.
    Kyle RA; Gertz MA; Greipp PR; Witzig TE; Lust JA; Lacy MQ; Therneau TM
    N Engl J Med; 1997 Apr; 336(17):1202-7. PubMed ID: 9110907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.
    Skinner M; Anderson J; Simms R; Falk R; Wang M; Libbey C; Jones LA; Cohen AS
    Am J Med; 1996 Mar; 100(3):290-8. PubMed ID: 8629674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine.
    Kyle RA; Greipp PR; Garton JP; Gertz MA
    Am J Med; 1985 Dec; 79(6):708-16. PubMed ID: 3934968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
    Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
    Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
    Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Congestive Heart Failure with Preserved Ejection Fraction in a Patient with Light Chain (AL) Amyloidosis and Multiple Myeloma.
    Carrizales-Sepúlveda EF; Ordáz-Farías A; Vera-Pineda R; Benavides-González MA; Flores-Ramírez R
    Am J Case Rep; 2017 Jul; 18():790-793. PubMed ID: 28701686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
    Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
    Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of primary amyloidosis with dimethylsulfoxide and cytoreductive chemotherapy.
    Shibuya T; Murakawa M; Tsuda Y; Harada M
    Intern Med; 1992 Apr; 31(4):544-8. PubMed ID: 1633367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Heart failure and arterial hypertension disclosing amyloidosis].
    Habbal R; Noureddine M; Hachim K; Zahraoui M; Azzouzi L; Fadouach S; Zaid D; Chraibi N
    Nephrologie; 1997; 18(3):91-4. PubMed ID: 9297135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapy options in systemic AL-amyloidosis with renal involvement].
    Hetzel GR; Schneider P; Mondry A; Heering P; Heyll A; Grabensee B
    Dtsch Med Wochenschr; 2000 Aug; 125(34-35):997-1002. PubMed ID: 11004911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.